Vaccine hesitancy is as much a governance challenge as a medical one. Discuss with reference to adolescent immunisation in India.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →In this answer
Vaccine hesitancy means delaying or refusing a vaccine even though it is available. India's National HPV Vaccination Campaign for 14-year-old girls began in February 2026. It has given over 1 crore doses and covers nearly 87% of the yearly cohort [1]. Hesitancy among parents of adolescents comes partly from medical doubts. It comes more from questions of trust, consent and delivery, which are governance problems.
Medical dimension
- Safety fears about vaccinating minors: these are handled through the AEFI (adverse events following immunisation) framework, Medical Officer supervision and links to 24×7 health centres [1].
- Doubts about one dose: WHO calls the single-dose schedule an off-label option, meaning it differs from the dosing on the manufacturer's licence [3]. Still, SAGE found its protection comparable to two doses, and 57 countries were using it by September 2024 [4].
- Screening out who should not be vaccinated: pregnant girls and girls with a yeast allergy or a past vaccine reaction are excluded [2].
Governance dimension
- Trust deficit and misinformation: ASHAs, ANMs, teachers and AIIMS doctors are used to win parents' trust [1]. Credible local messengers matter more than clinical data.
- Consent and autonomy: the drive is free, voluntary and needs parental consent [2]. This weighs the public health goal against family choice.
- Transparency through digital public infrastructure: on U-WIN, parents can book slots and download certificates, and officials can track each girl [1].
- Cooperative federalism: the earlier Bihar, Tamil Nadu and Sikkim programmes were merged into the national campaign. Six States report 100% coverage against a national figure of about 87%, so there are local trust gaps [1].
- Institutional permanence: as of December 2024, HPV vaccine was not part of the UIP (Universal Immunization Programme) [5]. A vaccine delivered only through a campaign can look temporary, and that feeds doubt.
- Self-reliance: CERVAVAC, India's first indigenous cervical cancer vaccine, makes supply more secure [5].
Way forward
- Bring HPV vaccine into the UIP and run a catch-up drive for ages 15–20, which WHO allows [3].
- Publish AEFI data regularly, run school-based awareness, and use local influencers.
Hesitancy is a medical question at the level of evidence but a governance question at the level of delivery. India's campaign shows that safety systems, consent, transparent digital tools and federal teamwork together build trust. Making it routine under the UIP would move India toward WHO's goal of having 90% of girls vaccinated, and help protect women's right to health under Article 21.
Sources
- 1PIB: India crosses 1 crore HPV vaccine doses (MoHFW release, 21 Nov 2026)1 crore doses and 87% coverage; AEFI and 24×7 links; frontline workers; U-WIN; merged State programmes; six States at 100%
- 2PIB: Free nationwide HPV vaccination campaign for girls aged 14 (Feb 2026)free, voluntary, parental consent; who is excluded
- 3WHO: WHO updates recommendations on HPV vaccination schedule (20 Dec 2022)single dose as an off-label option; one or two doses allowed for ages 15–20
- 4WHO: WHO adds an HPV vaccine for single-dose use (4 Oct 2024)single-dose evidence; 57 countries using it
- 5Lok Sabha Unstarred Question No. 3001 (13 Dec 2024)CERVAVAC is indigenous; HPV vaccine not in UIP